Shares of Nuformix plc (LON:NFX – Get Free Report) were up 14.3% on Tuesday . The company traded as high as GBX 0.16 ($0.00) and last traded at GBX 0.16 ($0.00). Approximately 2,005,000 shares were traded during trading, a decline of 37% from the average daily volume of 3,184,655 shares. The stock had previously closed at GBX 0.14 ($0.00).
Nuformix Trading Up 14.3 %
The company has a debt-to-equity ratio of 1.17, a quick ratio of 3.35 and a current ratio of 1.12. The company has a market cap of £1.31 million, a P/E ratio of -1.63 and a beta of 1.22. The stock has a 50-day moving average of GBX 0.17 and a two-hundred day moving average of GBX 0.19.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Further Reading
- Five stocks we like better than Nuformix
- Market Cap Calculator: How to Calculate Market Cap
- Why Block’s Key Components Make It a Solid Investment Choice
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Is Applied Digital’s Stock Set to Surge With NVIDIA’s Backing?
- Low PE Growth Stocks: Unlocking Investment Opportunities
- 4 Reasons to Consider Adding General Mills to Your Portfolio
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
